



## Clinical trial results:

**Randomised, double blind, parallel-groups, non-inferiority versus Flector® and superiority versus Placebo, Phase III clinical trial with Diclofenac Sodium 140 mg medicated plaster in patients with impact injuries of the limbs**

### Summary

EudraCT number	2017-003526-32
Trial protocol	DE HU IT
Global end of trial date	27 October 2018

### Results information

Result version number	v1 (current)
This version publication date	16 July 2021
First version publication date	16 July 2021

### Trial information

#### Trial identification

Sponsor protocol code	EQT7-16-02
-----------------------	------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Fidia Farmaceutici S.p.A
Sponsor organisation address	via Ponte della Fabbrica, Abano Terrme, Italy, 35031
Public contact	Flavia Baruzzi, LB Research S.r.l., 0039 031734908, ngiordan@fidiapharma.it
Scientific contact	Flavia Baruzzi, LB Research S.r.l., 3351042048 031734908, ngiordan@fidiapharma.it
Sponsor organisation name	Fidia Farmaceutici S.p.A
Sponsor organisation address	via Ponte della Fabbrica, Abano Terrme, Italy, 35031
Public contact	Giordan Nicola , Fidra Farmaceutici S.p.A, 0039 0498232512, ngiordan@fidiapharma.it
Scientific contact	Giordan Nicola , Fidra Farmaceutici S.p.A, 0039 0498232512, ngiordan@fidiapharma.it

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	27 October 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	27 October 2018
Global end of trial reached?	Yes
Global end of trial date	27 October 2018
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this trial is to show non-inferior efficacy of Test Diclofenac Sodium 140 mg medicated plaster (once a day) over a Reference Diclofenac epolamine (DIEP) 180 mg medicated plaster, Flector® (once a day), and that both Test and Reference are superior to Placebo plaster (once a day) in improving pain at rest at  $72 \pm 2$  hours (Day 4) after treatment start in patients with painful and phlogistic (inflammatory response) disease due to acute traumatic events (injury/contusion) of the limbs. A 100-mm Visual Analogue Scale (VAS) will be used for the assessment of pain at rest.

Protection of trial subjects:

Female of child-bearing potential (i.e. not in menopausal status from at least one year or permanently sterilized) had to have a negative urine pregnancy test prior the first investigational medicinal product (IMP) administration

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	25 May 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 44
Country: Number of subjects enrolled	Hungary: 165
Country: Number of subjects enrolled	Italy: 5
Worldwide total number of subjects	214
EEA total number of subjects	214

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23	0

months)	
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	207
From 65 to 84 years	7
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details: -

### Pre-assignment period milestones

Number of subjects started	214
----------------------------	-----

Number of subjects completed	214
------------------------------	-----

### Period 1

Period 1 title	overall trial (overall period)
----------------	--------------------------------

Is this the baseline period?	Yes
------------------------------	-----

Allocation method	Randomised - controlled
-------------------	-------------------------

Blinding used	Double blind
---------------	--------------

Roles blinded	Subject, Investigator, Monitor
---------------	--------------------------------

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Test Diclofenac Sodium 140 mg medicated plaster
------------------	---

Arm description:

Test Diclofenac Sodium 140 mg medicated plaster

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Diclofenac Sodium 140 mg medicated plaster
--	--

Investigational medicinal product code	
--	--

Other name	
------------	--

Pharmaceutical forms	Medicated plaster
----------------------	-------------------

Routes of administration	Topical
--------------------------	---------

Dosage and administration details:

T0 mg medicated plaster once a day

<b>Arm title</b>	DIEP 180 mg medicated plaster
------------------	-------------------------------

Arm description:

DIEP 180 mg medicated plaster

Arm type	Active comparator
----------	-------------------

Investigational medicinal product name	DIEP 180 mg medicated plaster
--	-------------------------------

Investigational medicinal product code	
--	--

Other name	
------------	--

Pharmaceutical forms	Medicated plaster
----------------------	-------------------

Routes of administration	Topical
--------------------------	---------

Dosage and administration details:

DIEP 180 mg medicated plaster once a day

Investigational medicinal product name	Placebo Plaster
--	-----------------

Investigational medicinal product code	
--	--

Other name	
------------	--

Pharmaceutical forms	Medicated plaster
----------------------	-------------------

Routes of administration	Topical
--------------------------	---------

Dosage and administration details:

Placebo Plaster once a day

<b>Arm title</b>	Placebo Plaster
Arm description: -	
Arm type	Placebo
Investigational medicinal product name	Placebo Plaster
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Medicated plaster
Routes of administration	Topical

Dosage and administration details:

Placebo plaster once a day

<b>Number of subjects in period 1</b>	Test Diclofenac Sodium 140 mg medicated plaster	DIEP 180 mg medicated plaster	Placebo Plaster
Started	71	72	71
Completed	71	72	71

## Baseline characteristics

## End points

### End points reporting groups

Reporting group title	Test Diclofenac Sodium 140 mg medicated plaster
Reporting group description:	Test Diclofenac Sodium 140 mg medicated plaster
Reporting group title	DIEP 180 mg medicated plaster
Reporting group description:	DIEP 180 mg medicated plaster
Reporting group title	Placebo Plaster
Reporting group description:	-
Subject analysis set title	IIT
Subject analysis set type	Full analysis
Subject analysis set description:	The Intention-to-treat (ITT) population, which included all randomized patients who took at least one plaster of study medication and had at least one post-baseline assessment of efficacy

### Primary: change from baseline in VAS score for pain at rest at 72 ± 2 hours (Day 4) after treatment start

End point title	change from baseline in VAS score for pain at rest at 72 ± 2 hours (Day 4) after treatment start
End point description:	
End point type	Primary
End point timeframe:	change from baseline at 72 ± 2 hours (Day 4) after treatment start

End point values	Test Diclofenac Sodium 140 mg medicated plaster	DIEP 180 mg medicated plaster	Placebo Plaster	IIT
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	71	72	71	214
Units: mm				
arithmetic mean (standard deviation)	-18.2 (± 17)	-17.1 (± 14.7)	-11.4 (± 14)	-18.2 (± 17)

### Statistical analyses

Statistical analysis title	mixed linear model with change from baseline to Da
Comparison groups	Test Diclofenac Sodium 140 mg medicated plaster v DIEP 180 mg medicated plaster v Placebo Plaster v IIT

Number of subjects included in analysis	428
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[1]</sup>
P-value	= 0.05
Method	mixed linear model

Notes:

[1] - The analysis of non-inferiority of Test (Diclofenac sodium 140 mg once a day) versus Reference (DIEP 180 mg once a day) on primary endpoint change from baseline in VAS score for pain at rest at 72 ± 2 hours (Day 4) was carried-out using a mixed linear model with change from baseline to Day 4 as dependent variable, treatment group and site as fixed factors of the model, baseline VAS for pain at rest as covariate and patient as random effect.



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

After the first dose of study medication until the end of the study.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.1
--------------------	------

### Reporting groups

Reporting group title	Diclofenac Sodium 140 mg medicated plaster
-----------------------	--

Reporting group description: -

Serious adverse events	Diclofenac Sodium 140 mg medicated plaster		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 71 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Diclofenac Sodium 140 mg medicated plaster		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 71 (7.04%)		
Nervous system disorders			
Hypoesthesia			
subjects affected / exposed	2 / 71 (2.82%)		
occurrences (all)	3		
Paresthesia			
subjects affected / exposed	1 / 71 (1.41%)		
occurrences (all)	1		
General disorders and administration site conditions			
Application site pruritus			
subjects affected / exposed	1 / 71 (1.41%)		
occurrences (all)	1		

Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	3 / 71 (4.23%)		
occurrences (all)	5		
Skin burning sensation			
subjects affected / exposed	3 / 71 (4.23%)		
occurrences (all)	5		

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported